New farnesyltransferase inhibitors in the phenothiazine series

被引:39
|
作者
Belei, Dalila [1 ]
Dumea, Carmen [1 ]
Samson, Alexandrina [1 ]
Farce, Amaury [2 ,3 ]
Dubois, Joelle [4 ]
Bicu, Elena [1 ]
Ghinet, Alina [1 ,2 ,5 ]
机构
[1] Alexandru Ioan Cuza Univ, Fac Chem, Dept Organ Chem, Iasi 700506, Romania
[2] Univ Lille Nord France, F-59000 Lille, France
[3] Inst Chim Pharmaceut Albert Lespagnol, EA GRIIOT, IFR114, F-59006 Lille, France
[4] Ctr Rech Gif, CNRS, Inst Chim Subst Nat, UPR2301, F-91198 Gif Sur Yvette, France
[5] UCLille, GRIIOT, Lab Pharmacochim, EA 4481, F-59046 Lille, France
关键词
Farnesyltransferase inhibitor; Anticancer agent; Phenothiazine; Triazole; FARNESYL TRANSFERASE INHIBITORS; PROTEIN FARNESYLTRANSFERASE; RAS GENES; N-RAS; CANCER; ASSAY; CARCINOMAS; BMS-214662; PANCREAS; AGENTS;
D O I
10.1016/j.bmcl.2012.06.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The biological screening of the chemical library of our Organic Chemistry Department, carried out on an automated fluorescence-based FTase assay, allowed us to discover that a phenothiazine derivative (1d) was an inhibitor of farnesyltransferase. Three new series of human farnesyltransferase inhibitors, based on a phenothiazine scaffold, were synthesized with protein farnesyltransferase inhibition potencies in the low micromolar range. Ester derivative 9d was the most active compound in these series. Four synthesized compounds were evaluated for their antiproliferative activity on a NCI-60 cancer cell line panel. The modest results obtained in this preliminary investigation showed that mixing the phenothiazine and the 1,2,3-triazole motif in the structure of a single compound can lead to new scaffolds in the field of farnesyltransferase inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4517 / 4522
页数:6
相关论文
共 50 条
  • [41] Farnesyltransferase inhibitors as radiation sensitizers
    Brunner, TB
    Gupta, AK
    Shi, Y
    Hahn, SM
    Muschel, RJ
    Mckenna, WG
    Bernhard, EJ
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (07) : 569 - 576
  • [42] Progeria, the nucleolus and farnesyltransferase inhibitors
    Mehta, Ishita S.
    Bridger, Joanna M.
    Kill, Ian R.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2010, 38 : 287 - 291
  • [43] Farnesyltransferase inhibitors as radiation sensitizers
    McKenna, WG
    Muschel, RJ
    Gupta, AK
    Hahn, SM
    Bernhard, EJ
    SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (03) : 27 - 32
  • [44] Quantitative structure activity relationship studies on a series of tetrahydroquinoline-based farnesyltransferase inhibitors
    Chaurasia, SH.
    Srivastava, A. K.
    Math, A.
    Srivastava, M. K.
    Pandey, A.
    OXIDATION COMMUNICATIONS, 2007, 30 (04): : 778 - 787
  • [45] Farnesyltransferase inhibitors: mechanism and applications
    Prendergast, GC
    Rane, N
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (12) : 2105 - 2116
  • [46] Farnesyltransferase inhibitors - Preclinical development
    Kohl, NE
    ANTICANCER MOLECULES: STRUCTURE, FUNCTION, AND DESIGN, 1999, 886 : 91 - 102
  • [47] IDENTIFICATION OF RAS FARNESYLTRANSFERASE INHIBITORS
    TAMANOI, F
    ESSON, K
    GOMEZ, R
    WOOD, D
    UH, M
    HARA, M
    AKASAKA, K
    OKABE, M
    NAKANO, H
    FASEB JOURNAL, 1993, 7 (07): : A1049 - A1049
  • [48] Farnesyltransferase inhibitors: promises and realities
    Cox, AD
    Der, CJ
    CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 388 - 393
  • [49] New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
    A Cristina Gonçalves
    Ana Oliveira
    Diana Moreira
    Silvia Neves
    Vera Alves
    Teresa Silva
    Luís Mesquita
    Henriqueta Coimbra
    Marília Dourado
    José M Nascimento-Costa
    Ana B SarmentoRibeiro
    BMC Proceedings, 4 (Suppl 2)
  • [50] On the discovery of new potent human farnesyltransferase inhibitors: emerging pyroglutamic derivatives
    Homerin, Germain
    Lipka, Emmanuelle
    Rigo, Benoit
    Farce, Amaury
    Dubois, Joelle
    Ghinet, Alina
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2017, 15 (38) : 8110 - 8118